ALS acquires stake in European Pharmaceutical business
Filed with ASX · · 8 pages · English
Watch ALS' latest callALS (ASX:ALQ) Q4 2026 Earnings Call · Replay · May 17Read the transcript of ALS (ASX:ALQ) Q4 2026 Earnings CallALS Limited (ASX: ALQ), a leading global testing, inspection and certification business, today announced the acquisition of an initial 49% interest in NUVISAN, a pharmaceutical testing business with operations in Germany and France. Founded in 1979, NUVISAN is privately owned with over 1,000 employees and generated ~EUR185 million of revenue and ~EUR40 million of adjusted EBITDA in FY21. NUVISAN o
Earlier from ALS
- Managing Director and CEO 2021 AGM Address
- Chairmans 2021 AGM Address
- ALS Investor Presentation FY21
- ALS Full Year Results FY21
- ALS Full Year Statutory Accounts FY21
Later from ALS
- Half Yearly Report 30 September 2021(including Appendix 4D)
- ALS Investor Presentation Half Year Results HY2022
- PRN: Perenti divests MinAnalytical to ALS Limited for $43.6M
- ALS Geochemistry operation acquires MinAnalytical
- ALS updates FY22 NPAT guidance
Follow ALS into a list and get an email when it puts out news.
Follow ALS